CEBINA Collaborates With Charles River Laboratories To Accelerate Neuroscience Research

CEBINA (Central European Biotech Incubator and Accelerator) and Charles River Laboratories International, Inc. announced a planned partnership as part of the DanubeNeuro acceleration program, pioneering an innovative research process that would lead to new drugs and novel technologies in the zone of neurodegeneration.

The DanubeNeuro acceleration program by CEBINA promotes and develops innovative research projects and has the potential to create novel drugs, imaging techniques, diagnostic methods, and disease biomarkers in the field of diseases linked to neuroscience. Projects selected for acceleration as part of the DanubeNeuro program will benefit from  Charles Rivers's large-scale expertise and knowledge in CNS and drug discovery development and CEBINA’s experience in other acceleration programs. This collaboration will boost the drive for innovation in neurodegeneration.

Aidan Synnott, PhD, Corporate Vice President, Global Discovery Services at Charles River, said in a statement, “We are eager to contribute our expertise to this acceleration program and support the next generation of breakthroughs in neuroscience. Being part of DanubeNeuro and collaborating with CEBINA aligns perfectly with our commitment to advancing scientific research and innovation."

As lifespans continue, a neurodegenerative disorder like age-related conditions increases and sets forth globally unachieved medical needs with substantial and growing public health and societal impacts. It is vitally essential to accelerate the development of innovative academic ideas into drug development that address complex diseases such as Alzheimer’s and Parkinson’s.

Eszter Nagy, MD, PhD, CEO&CSO of CEBINA, also added, "We are thrilled to partner with Charles River for our new acceleration program, DanubeNeuro. Charles River’s unparalleled expertise in the development of neurotherapeutics will significantly support us in the selection and development process of product candidates. This collaboration will not only bring forth projects with the highest potential but also de-risks this complex and challenging process for investors. We are prepared to reach our ultimate goal: improving the lives of patients and their desperate families." 

“Since we launched DanubeNeuro 4 months ago, we have been impressed by the quality and quantity of academic research programs with highly innovative propositions and novel, disease-modifying approaches to neurodegeneration. By collaborating with Charles River, we are tapping into vast experience and hands-on know-how in CNS drug development that substantially strengthens our initiative to execute drug discovery projects and deliver high-quality product candidates for further development,” stated Vanja Nagy, PhD, Scientific Program Director of DanubeNeuro.